NCT06232759View on ClinicalTrials.gov

TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

October 30, 2023

Study Completion Date

January 20, 2024

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab

Patients with unresectable hepatocellular carcinoma were received transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab

Trial Locations (1)

530021

Jian-Hong Zhong, Nanning

All Listed Sponsors
lead

Guangxi Medical University

OTHER